BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38429657)

  • 1. Few-shot genes selection: subset of PAM50 genes for breast cancer subtypes classification.
    Okimoto LYS; Mendonca-Neto R; Nakamura FG; Nakamura EF; Fenyö D; Silva CT
    BMC Bioinformatics; 2024 Mar; 25(1):92. PubMed ID: 38429657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research-based PAM50 signature and long-term breast cancer survival.
    Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
    Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
    Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
    BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
    Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
    Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
    Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
    BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
    Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
    Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
    Picornell AC; Echavarria I; Alvarez E; López-Tarruella S; Jerez Y; Hoadley K; Parker JS; Del Monte-Millán M; Ramos-Medina R; Gayarre J; Ocaña I; Cebollero M; Massarrah T; Moreno F; García Saenz JA; Gómez Moreno H; Ballesteros A; Ruiz Borrego M; Perou CM; Martin M
    BMC Genomics; 2019 Jun; 20(1):452. PubMed ID: 31159741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes.
    Ochoa S; de Anda-Jáuregui G; Hernández-Lemus E
    Front Oncol; 2020; 10():845. PubMed ID: 32528899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
    Jaber MI; Song B; Taylor C; Vaske CJ; Benz SC; Rabizadeh S; Soon-Shiong P; Szeto CW
    Breast Cancer Res; 2020 Jan; 22(1):12. PubMed ID: 31992350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtyping for clinically defined breast cancer subgroups.
    Zhao X; Rødland EA; Tibshirani R; Plevritis S
    Breast Cancer Res; 2015 Feb; 17(1):29. PubMed ID: 25849221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.
    Klopfenstein Q; Derangère V; Arnould L; Thibaudin M; Limagne E; Ghiringhelli F; Truntzer C; Ladoire S
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.
    Milioli HH; Vimieiro R; Riveros C; Tishchenko I; Berretta R; Moscato P
    PLoS One; 2015; 10(7):e0129711. PubMed ID: 26132585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications.
    Allott EH; Shan Y; Chen M; Sun X; Garcia-Recio S; Kirk EL; Olshan AF; Geradts J; Earp HS; Carey LA; Perou CM; Pfeiffer RM; Anderson WF; Troester MA
    Breast Cancer Res Treat; 2020 Jan; 179(1):185-195. PubMed ID: 31535320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixture classification model based on clinical markers for breast cancer prognosis.
    Zeng T; Liu J
    Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
    Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
    Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-driven integrated classification of breast cancer validated in over 7,500 samples.
    Ali HR; Rueda OM; Chin SF; Curtis C; Dunning MJ; Aparicio SA; Caldas C
    Genome Biol; 2014 Aug; 15(8):431. PubMed ID: 25164602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of subtype-specific breast cancer surface protein biomarkers via a novel transcriptomics approach.
    Mercatelli D; Formaggio F; Caprini M; Holding A; Giorgi FM
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34750607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
    Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.